To establish a cutoff value using a ratio of CSF tau to Aβ42 (tau/Aβ42) for distinguishing patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects. The investigators hypothesize that a cutoff can be found that has at least 80% sensitivity and 60% specificity.
This study will enroll 50 AD subjects, 50 normal controls and approximately 20 subjects with non-AD dementia. There will be 2 visits (up to 30 days apart), and a telephone follow-up visit. This protocol does not include treatment of subjects. Lumbar puncture and phlebotomy are routine clinical tasks and are associated with a low level of risk. All adverse events will be documented and reviewed by the PI.
Study Type
OBSERVATIONAL
Enrollment
40
Duke Health Center at Morreene Road
Durham, North Carolina, United States
Ratio of CSF tau to Aβ42 (tau/Aβ42)
CSF will be collected in clinic and shipped frozen to Merck's Clinical Development Lab for testing. Any remaining samples will be kept up to 20 years.
Time frame: CSF will be collected at Visit 1 (up to 30 days after the screening visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.